Research programme: angiogenesis inhibitors - Bausch & Lomb/Cephalon

Drug Profile

Research programme: angiogenesis inhibitors - Bausch & Lomb/Cephalon

Alternative Names: Eye disorder therapeutics - Bausch & Lomb/Cephalon

Latest Information Update: 30 Oct 2007

Price : $50

At a glance

  • Originator Cephalon
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 27 Oct 2007 Bausch and Lomb has been acquired by Warburg Pincus
  • 13 Dec 2005 Preclinical trials in Diabetic macular oedema in USA (unspecified route)
  • 13 Dec 2005 Preclinical trials in Age-related macular degeneration in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top